表紙
市場調查報告書
商品編碼
1031005

腰椎間盤突出症(坐骨神經痛)市場:到 2030 年的流行病學和市場預測

Lumbar Radiculopathy (Sciatica)| Primary Research (KOL's Insight) | Market Intelligence | Epidemiology & Market Forecast - 2030

出版日期: | 出版商: Mellalta Meets LLP | 英文 181 Pages | 訂單完成後即時交付

價格
  • 全貌
  • 簡介
  • 目錄
簡介

腰椎間盤突出治療的市場規模預計將在整個預測期內高速增長,預計從 2017 年到 2030 年將增長。這種增長的主要驅動力是針對慢性 LSR/坐骨神經痛的新藥的推出。

坐骨神經痛(醫學上也稱為腰神經根病或腰□神經根病 (LSR))是一種從臀部深處開始並延伸到大腿和/或腿部的神經痛。是。坐骨神經痛是由於椎間盤突出導致腰椎神經根受壓和脊神經通過的骨間隙變窄(椎管狹窄)引起的。

大約90%的坐骨神經痛是由於椎間盤突出壓迫腰椎和□骨的神經根引起的,之後椎管狹窄、椎管狹窄也會引起坐骨神經痛..坐骨神經痛也可能在懷孕期間發生,在極少數情況下,可能會發生約 8% 的梨狀肌症候群,其中梨狀肌縮短並壓迫坐骨神經。椎間盤突出、扭傷、帶狀皰疹和腰椎退變可導致急性坐骨神經痛持續數天至數週,但除非進行手術,否則腰椎和椎間盤退變會持續慢性坐骨神經痛。

坐骨神經痛通常以劇烈疼痛和炎症為特徵。坐骨神經痛可以發生在任何年齡,但它通常發生在 40 多歲的男性和 50 多歲和 60 多歲的女性中。

本報告調查了腰椎間盤突出症(坐骨神經痛)市場,並提供了市場概況,以及按應用、組件、部署、最終用戶、地區和進入市場的公司概況的趨勢。

目錄

執行摘要

  • 主要發現

腰神經痛 (坐骨神經痛) 疾病的背景

  • 腰椎間盤突出症(坐骨神經痛)的定義
  • 症狀和原因
  • 病理生理學
  • 診斷和診斷建議
  • 鑑別診斷

流行病學和患者群體

  • 主要發現
  • 技術和數據來源
    • 各國流行率(美國、德國、法國、意大利、西班牙、英國和日本)
    • 各國慢性腰神經痛(坐骨神經痛)病例
    • 慢性腰椎神經痛(坐骨神經痛)的國別治療及難治性病例
  • 腰神經痛(坐骨神經痛)流行病學和模型參數的主要來源
    • 美國
    • 德國
    • 法國
    • 意大利
    • 西班牙
    • 英國
    • 日本

當前的治療方法和醫療實踐

  • 治療和醫療實踐
  • 藥理學方法
  • 非藥理學方法

未滿足的需求

新治療

  • 流水線概覽
  • 腰椎間盤突出症(坐骨神經痛)治療開發管道
    • 產品分析
      • 地塞米松磷酸鈉凝膠(Scilex Pharmaceuticals)
        • 產品簡介
        • 臨床開發
        • 到 2030 年的銷售和市場機會
      • Condriase (Seikagaku Corporation)
        • 產品簡介
        • 臨床開發
        • 到 2030 年的銷售和市場機會
      • 可樂定緩釋劑(Sollis Therapeutics)
        • 產品簡介
        • 臨床開發
        • 到 2030 年的銷售和市場機會
      • ETX-810 (Eliem Therapeutics Inc)
        • 產品簡介
        • 臨床開發
        • 到 2030 年的銷售和市場機會
      • 緩釋地塞米松 (SpineThera)
        • 產品簡介
        • 臨床開發
        • 到 2030 年的銷售和市場機會
      • BOL-DP-o-04 (Breath of Life International Pharma Ltd)
        • 產品簡介
        • 臨床開發
      • KLS-2031(可隆生命科學)
        • 產品簡介
        • 臨床開發

腰神經痛(坐骨神經痛)-價格和報銷

未來的治療範式

  • 腰椎間盤突出症(情境性神經痛) 競爭對手狀態 預期批准
  • 未來的處理算法和競爭對手定位
  • 新療法的重要數據匯總

當前和新治療的年度成本

市場展望

  • 主要調查結果
  • 到 2030 年的國家市場預測
    • 2017-2030年主要醫藥市場治療腰椎間盤突出症(坐骨神經痛)藥物銷售情況
    • 腰椎間盤突出症(坐骨神經痛)治療及患者用藥比例

按國家/地區劃分的市場預測

  • 美國
  • 德國
  • 法國
  • 意大利
  • 西班牙
  • 英國
  • 日本

市場促進因素和抑制因素

目錄
Product Code: MM202034

The Lumbar Radiculopathy/LSR (Sciatica) therapeutic market is expected to experience high growth throughout our study period, increasing from 2017 to 2030. The main drivers of this growth will be the launch of new drugs in chronic LSR/sciatica setting, e.g., Dexamethasone sodium phosphate gel / SEMDEXA (Scilex Pharmaceuticals), Condoliase / HERNICORE (Seikagaku Corporation / Ferring Pharmaceuticals), ETX-810 (Eliem Therapeutics Inc), Extended-release Clonidine / Clonidine micropellet (Sollis Therapeutics) and extended-release dexamethasone (SpineThera).

Sciatica (also refferred to as Lumbar Radiculopathy or lumbosacral radiculopathy (LSR) , which is medically defined as lumbar radiculopathy, is nerve pain that originates deep in the buttock and travels down to the thigh and/or leg. Sciatica is commonly caused when a herniated disc or narrowing of the bony opening for spinal nerves (foraminal spinal stenosis) compresses a nerve root in the lumbar spine.

Approximately 90% of cases of sciatica is due to spinal disc herniation pressing on one of the lumbar or sacral nerve roots, followed by spinal stenosis or the narrowing of the spinal canal which is another reason for sciatica pain. Sciatica may also occur during pregnancy and up to 8% cases rarely arises from Piriformis syndrome in which the shortening of piriformis muscle exerts pressure on the sciatic nerve. However, Disc herniation, back sprain, shingles, and degenerative lumbar spine can all cause acute sciatica, lasting from days to weeks, but degeneration of the lumbar spine and discs leads to chronic sciatica that persists unless a surgical intervention is performed.

Sciatica is often characterized by extreme pain and inflammation. Sciatica can occur at any age but often effects men beginning in their 40s and women in their 50s and 60s.

Sciatica - Prevalence (Epidemiology)

The criteria used to diagnose Lumbar Radiculopathy (Sciatica) are those of the diagnostic guidelines provided by various governing bodies. According to these criteria and the KOL perspective, there is no specific tests for sciatica and current diagnosis are mainly done by using tools like neuroimaging, MRI scan, CT myelography, Electromyography (EMG), straight leg raising test and Cerebrospinal fluid analysis. As the diagnosis of lumbosacral radiculopathy (Sciatica) is not specific, there are other conditions that can be differentiated due to the radicular pain. The other conditions in the differential diagnosis of lumbosacral radiculopathy include herniated disc, lumbosacral plexopathy, lumbar spinal stenosis, mononeuropathies, diabetic amyotrophy, cauda equina syndrome, and non-radicular back pain.

"The total prevalent cases of lumbosacral radicular pain (LSR) / sciatica in the G7 countries are projected to increase from 24 million in 2017 to XX million by 2030 with a CAGR of XX% for the study period (2017-2030 ). The United States was estimated to have the highest prevalence of lumbar radiculopathy (sciatica) cases in 2017."

Sciatica - Current Market Size & Forecast Trends

Current market of Sciatica holds treatment options that are supportive like a conservative (nonsurgical) and surgical approaches. Conservative treatment of sciatica further includes physical therapy, behavioral therapies, or pharmacological therapies. Pharmacological therapies includes medications such as non-steroidal anti-inflammatory drugs (NSAIDs), epidural steroid injections (ESIs), opioids etc. that has been used over-the counter and were observed to reduce the swelling and sciatic pain. Patients are treated with a wide variety of medication first and referred for epidural steroid injections as a second step if they fail to respond to pain medication.

"Epidural injections are common. An estimated 10 million to 11 million injections (2.2 million in the Medicare population) are administered annually in the United States. Despite of widespread utilization of ESIs, concerns persist in the market about particulate steroids and potential side effect and safety concerns (e.g., stroke) from current off-label use. As a result, a significant unmet medical need exists within the market for a potent, non-particulate ESI formulation that demonstrates safety and effectiveness in controlled clinical trial evaluations. Therefore, current sciatica market exhibit a critical unmet need to improve the quality of life of the patients since there are no FDA approved therapies to treat the indication and the off-label therapies have several side effects."

The Lumbar Radiculopathy / LSR (Sciatica) market is expected to see high growth during the forecast period. The market in the G7 countries is expected to reach $18 billion in 2030. The lumbar radiculopathy (sciatica) treatment market is divided into acute and chronic lumbar radiculopathy.

"Approximately 70% of acute cases will be recovered with primary treatments and the remaining 30% are expected to fall into the chronic group, referred to here as chronic LSR. "

The market for acute lumbar radiculopathy (Sciatica) is relatively large compared to the market for chronic lumbar radiculopathy (Sciatica) due to the high number of patients and the increase in primary care prescriptions each year.

Report Highlights:

  • Lumbar Radiculopathy (Sciatica)- Current Market Trends
  • Lumbar Radiculopathy (Sciatica)- Current & Forecasted Cases across the G7 Countries
  • Lumbar Radiculopathy (Sciatica)- Market Opportunities And Sales Potential for Agents
  • Lumbar Radiculopathy (Sciatica)- Patient-based Market Forecast to 2030
  • Lumbar Radiculopathy (Sciatica)- Untapped Business Opportunities
  • Lumbar Radiculopathy (Sciatica)- Product Positioning Vis-a-vis Competitors' Products
  • Lumbar Radiculopathy (Sciatica)- KOLs Insight

Table of Contents

Executive Summary

  • Key Findings

Lumbar Radiculopathy (Sciatica) Disease Background

  • Lumbar Radiculopathy (Sciatica) Definition
  • Symptoms & Causes
  • Pathophysiology
  • Diagnosis & Diagnostic Recommendations
  • Differential Diagnosis

Epidemiology and Patient Populations

  • Key Findings
  • Methods and data Sources
    • Country Specific Prevalent Population (US, Germany, France, Italy, Spain, UK, and Japan)
    • Country Specific Chronic Prevalent cases of Lumbar Radiculopathy (Sciatica)
    • Country Specific Treated & Refractory Cases of Chronic Lumbar Radiculopathy (Sciatica)
  • Key Sources for Lumbar Radiculopathy (Sciatica) Epidemiology and Model Parameters
    • United States
      • United States Prevalent Population of Lumbar Radiculopathy (Sciatica)
      • United States Chronic Prevalent cases of Lumbar Radiculopathy (Sciatica)
      • United States Treated & Refractory Cases of Chronic Lumbar Radiculopathy (Sciatica)
    • Germany
      • Germany Prevalent Population of Lumbar Radiculopathy (Sciatica)
      • Germany Chronic Prevalent cases of Lumbar Radiculopathy (Sciatica)
      • Germany Treated & Refractory Cases of Chronic Lumbar Radiculopathy (Sciatica)
    • France
      • France Prevalent Population of Lumbar Radiculopathy (Sciatica)
      • France Chronic Prevalent cases of Lumbar Radiculopathy (Sciatica)
      • France Treated & Refractory Cases of Chronic Lumbar Radiculopathy (Sciatica)
    • Italy
      • Italy Prevalent Population of Lumbar Radiculopathy (Sciatica)
      • Italy Chronic Prevalent cases of Lumbar Radiculopathy (Sciatica)
      • Italy Treated & Refractory Cases of Chronic Lumbar Radiculopathy (Sciatica)
    • Spain
      • Spain Prevalent Population of Lumbar Radiculopathy (Sciatica)
      • Spain Chronic Prevalent cases of Lumbar Radiculopathy (Sciatica)
      • Spain Treated & Refractory Cases of Chronic Lumbar Radiculopathy (Sciatica)
    • United Kingdom
      • United Kingdom Prevalent Population of Lumbar Radiculopathy (Sciatica)
      • United Kingdom Chronic Prevalent cases of Lumbar Radiculopathy (Sciatica)
      • United Kingdom Treated & Refractory Cases of Chronic Lumbar Radiculopathy (Sciatica)
    • Japan
      • Japan Prevalent Population of Lumbar Radiculopathy (Sciatica)
      • Japan Clinical Chronic Prevalent cases of Lumbar Radiculopathy (Sciatica)
      • Japan Treated & Refractory Cases of Chronic Lumbar Radiculopathy (Sciatica)

Current Therapies and Medical Practice

  • Treatments & Medical Practices
  • Pharmacological Approaches
  • Non-Pharmacological Approaches

Unmet Needs

Emerging Therapies

  • Pipeline Overview
  • Therapeutic Developments Pipeline for Lumbar Radiculopathy (Sciatica)
    • Product Analysis
      • Dexamethasone sodium phosphate gel (Scilex Pharmaceuticals)
        • Product Profile
        • Clinical Development
        • Sales & Market Opportunity by 2030
      • Condoliase (Seikagaku Corporation)
        • Product Profile
        • Clinical Development
        • Sales & Market Opportunity by 2030
      • Clonidine extended release (Sollis Therapeutics)
        • Product Profile
        • Clinical Development
        • Sales & Market Opportunity by 2030
      • ETX-810 (Eliem Therapeutics Inc)
        • Product Profile
        • Clinical Development
        • Sales & Market Opportunity by 2030
      • Sustained-release dexamethasone (SpineThera)
        • Product Profile
        • Clinical Development
        • Sales & Market Opportunity by 2030
      • BOL-DP-o-04 (Breath of Life International Pharma Ltd)
        • Product Profile
        • Clinical Development
      • KLS-2031 (Kolon Life Science)
        • Product Profile
        • Clinical Development

Lumbar Radiculopathy (Sciatica)- Pricing & Reimbursement

Future Treatment Paradigm

  • Lumbar Radiculopathy (Sciatica) Competitor Landscape and Approvals Anticipated
  • Future Treatment Algorithms and Competitor Positioning
  • Key Data Summary for Emerging Treatment

Annual Cost of Current & Emerging Therapies

Market Outlook

  • Key Findings
  • Country Specific Market Forecast to 2030
    • Sales of Drugs to Treat Lumbar Radiculopathy (Sciatica) in the Major Pharmaceutical Markets, 2017-2030
    • Patient Share of Lumbar Radiculopathy (Sciatica) Therapies and by Drug

Market Forecast by Country

  • United States
    • United States Market for Lumbar Radiculopathy (Sciatica) 2020-2030 (USD Million)
    • United States Market for Lumbar Radiculopathy (Sciatica) by Therapies 2020-2030 (USD Million)
  • Germany
    • Germany Market for Lumbar Radiculopathy (Sciatica) 2020-2030 (USD Million)
    • Germany Market for Lumbar Radiculopathy (Sciatica) by Therapies 2020-2030 (USD Million)
  • France
    • France Market for Lumbar Radiculopathy (Sciatica) 2020-2030 (USD Million)
    • France Market for Lumbar Radiculopathy (Sciatica) by Therapies 2020-2030 (USD Million)
  • Italy
    • Italy Market for Lumbar Radiculopathy (Sciatica) 2020-2030 (USD Million)
    • Italy Market for Lumbar Radiculopathy (Sciatica) by Therapies 2020-2030 (USD Million)
  • Spain
    • Spain Market for Lumbar Radiculopathy (Sciatica) 2020-2030 (USD Million)
    • Spain Market for Lumbar Radiculopathy (Sciatica) by Therapies 2020-2030 (USD Million)
  • United Kingdom
    • United Kingdom Market for Lumbar Radiculopathy (Sciatica) 2020-2030 (USD Million)
    • United Kingdom Market for Lumbar Radiculopathy (Sciatica) by Therapies 2020-2030 (USD Million)
  • Japan
    • Japan Market for Lumbar Radiculopathy (Sciatica) 2020-2030 (USD Million)
    • Japan Market for Lumbar Radiculopathy (Sciatica) by Therapies 2020-2030 (USD Million)

Market Drivers and Constraints

  • What Factors Are Driving the Market for Lumbar Radiculopathy (Sciatica)?
  • What Factors Are Constraining the Market for Lumbar Radiculopathy (Sciatica)?